knowledge -WSS

knowledge

author：Wikipedia 2025-09-06 02:11:21 - browse：35788

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Amylyx's ALS drug launch starts strong. It could be trouble for FDA

explore

WSS

Medical mystery: When a cough is not just a cough

Industry veterans launch new biotech VC with $310M

Emergent cuts jobs, executive role in business shake

Maui's cultural, historic landmarks damaged in the devastating wildfires

Methadone doses haven’t kept up in the age of fentanyl

Maui's cultural, historic landmarks damaged in the devastating wildfires

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Medicare details structure of new drug price negotiation program

What to know about Virgin Galactic's 1st mission taking paying customers to space

Peter Hotez and the public health issue of online harassment

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Peter Hotez and the public health issue of online harassment

A disappointing year of Humira biosimilars

Activists slam private health insurers over coverage restrictions

NIH trials fail to test meaningful long Covid therapies, experts say

Wikipedia

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Medicare threatens to cut off funding for HCA's Mission hospital

A disappointing year of Humira biosimilars

FDA panel issues narrow recommendation for Covid vaccine booster doses

focus

hotspot

explore

entertainment